US Dollar vs Yen

登録してリアルタイムのチャート、分析ツール、価格を入手してください。

ホーム
投資
株式
アメリカ
NASDAQ
Arco Platform Ltd (ARCE)
Arco Platform Ltd (ARCE) ニュース

Arco Platform Ltd (ARCE)

13.98

0.00

(0.00%)

終了 7月13日 5:00AM

0.00

0.00

(0.00%)

取引時間後: -

リアルタイムのストリーミング引用、アイデア、ライブディスカッションのハブ

プレミアム

Form SCHEDULE 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]

Form 15-12G - Securities registration termination [Section 12(g)]

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]

Form SC 13G - Statement of acquisition of beneficial ownership by individuals

Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]

Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]

Form SC 13E3/A - Going private transaction by certain issuers: [Amend]

Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments

Arco Announces Merger Completion and Becomes a Private Company

Arco Platform Limited (Nasdaq: ARCE) (“Arco” or the “Company”), a leading operating system for K-12 schools, announced today the completion of...

Arco Announces Shareholders’ Approval of Merger Agreement to Go Private

Arco Platform Limited (Nasdaq: ARCE) (“Arco” or the “Company”), a leading operating system for K-12 schools announced today that at an...

Arco to Provide Supplemental Materials for Extraordinary General Meeting of Shareholders

Arco Platform Limited (Nasdaq: ARCE) (“Arco” or the “Company”), a leading operating system for K-12 schools, previously announced that it has...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Arco to Hold Extraordinary General Meeting of Shareholders

Arco Platform Limited (Nasdaq: ARCE) (“Arco” or “Company”), a leading operating system for K-12 schools, today announced that it has called an...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

stoxjock

stoxjock 2分前

"This in NO WAY is specific to or suggest any limitations as to when the 75/25% ENDS OR IS ONLY GOOD FOR A LIMITED SPECIFIC CUT OFF ON RETURNS.............in any way FORM OR FASHION"

EXACTLY, BBAN! The Court itself Clearly set the "75%/25% SPLIT" BEFORE POR7 was "Ratified" and this wa

Eli's Gone

Eli's Gone 3分前

Eli's Gone

Eli's Gone 3分前

learningcurve2020

learningcurve2020 3分前

Good point on GBM’s rarity in children. But nothing at all normal about a trial that last recruited ten years ago with no follow up trials and still allegedly waiting for a decision. NWBO PR’d they had pediatric plan approved until they divulged in a report they didn't and still don’t. Yes, cash

FormalMHRAconsultant

FormalMHRAconsultant 6分前

Look at what's stacked up. The external-control method drew a documented, published reliability critique (Rahman & Trippa, 2023). NWBO then built and submitted an entire new IPD-based package three datasets, PSM, IPW, E-values, and Rosenbaum's Gamma. And the review has now run 900+ days with no deci

2BAD4U

lol Tards keep posting hoping to get someone to respond--ON A WEEKEND lmao
$Weeeeeeeeeeeeeeeeeeeeeeeeee 🚀💰️(SOON) 😎

amelia43

amelia43 12分前

I said that so long ago that if anything happens to Trump we are beyond done. And anything can happen to Trump anytime.

Just1time

Just1time 15分前

There are many posters on here that say the same thing whether they have 10 or 1000 posts

BBANBOB

BBANBOB 17分前

NEWFLOW
None of AI responses on the 75/25% makes any real sense as WE KNOW FOR FACT the THE TPS GROUP fought in court for almost 2 yrs to have the ABSOULUTE PRIORITY REMOVED ! AND SUCCEDED IN GETTING IT DROPPED/CANCELLED IN THIS SITUATION.

So I guess my question is HOW D

learningcurve2020

learningcurve2020 18分前

So you think that CTBVEAG mention wasn’t about L? And why exactly would LP not want to explain that to investors instead letting the share price crater?

Lifetime

Lifetime 19分前

Due Dilligence to this crew is AI and message board posts

Goats'nCrows

Goats'nCrows 19分前

If you were right, NWBO would never have needed to submit the PSM analysis, and we'd have seen an MHRA approval on the MAIC alone by now. We haven't. Instead, NWBO had to build and submit the entire IPD/PSM package to rescue the MAA.

FMHRAC, thanks for your posts and reading them has

stoxjock

stoxjock 21分前

BBAB,
We won't know Until IF/When any of the "PAC Distributions: occur and I am Not even Sure that PAC Itself held ALL the Assets of Erstwhile WaMu...

Yes, We are All So Worn Out waiting these 15 - 18 years But maybe this Delay was All "By Design" so that we'll accept whatever

GetSeriousOK

GetSeriousOK 21分前

The "BIELIEVERS" are seeing a line on Electrome's website where it says they have 100,000 units in stock.

It's a lie, IMO, as are many of the things on the Electrome website.

People are taking that "100,000 in stock" line as gospel, but they aren't bothering to access a

FormalMHRAconsultant

FormalMHRAconsultant 23分前

The absence of a pediatric trial almost certainly reflects mundane factors, not anything about the vaccine's efficacy or safety so I wouldn't read it as a negative signal. The biggest reason is money: NWBO has been chronically cash-strapped for years (going concern, ~$1.8M in cash) and couldn't even

learningcurve2020

learningcurve2020 23分前

Not for the effort but for the total lack of transparency that wipes out shareholders.

>>Nobody can blame NWBO for the effort

DoYourOwnDD

DoYourOwnDD 24分前

Do you think public companies vote on canceling an agreement?

Now able to be purchased
No, the perpetual license was purchased. Licenses are the right to use something. That's how licenses work. What are you even debating here?

This whole post is nonsensical. Ra

RuudSaltis

RuudSaltis 25分前

The only reason is because it’s a major indirect announcement. CEO Marvel/Polariton is imo important and he agrees openly it’s a damn good product!

LutherTiggs

LutherTiggs 26分前

Agree. I have same question. I'm not seeing how LWLG could be involved with 5 million in shipments of PICs without reporting so...not to mention that Yves still claiming no volume shipments until second half 2027. What I did see was a secondary article including the following excerpt referencing

Vexari

Vexari 26分前

Subject matter

Without the investorshub.advfn.com/boards/read_msg.aspx?message_id=172237216 ad hominem

Meaning essential

Distractions not

But, but, but.. what if that is the subject matter?

BBANBOB

BBANBOB 27分前

LARGE GREEN

I know how you and I and many other here feel and I for one will take a court filing om 2 separate occasions as a CYA so that NO ONE CAN HAVE A LEGAL LEG TO STAND ON if any decided to legally question the 75/25%

Time will tell and time will tell all

learningcurve2020

learningcurve2020 27分前

Can you speculate why no pediatric trial after all these years with a nearly side effects free vaccine?

FormalMHRAconsultant

FormalMHRAconsultant 28分前

Just to be absolutely clear. I am personally convinced that DCVAXL will be approved based on the IPD/PSM package; I am NOT convinced DCVAXL would have been approved on MAIC. I also believe that NWBO will be bought out 2 to 3 years after MHRA approval.

learningcurve2020

learningcurve2020 29分前

>>For the CEOUnlimited Leverage: A successful CEO without a long-term contract can renegotiate their compensation and equity packages annually based on recent performance.

Freedom to Exit: At-will CEOs can resign and exit the company quickly without violating non-compete clauses or fa

LessIsMore

LessIsMore 30分前

NWBO had to build and submit the entire IPD/PSM package to rescue the MAA

Finally, something we can agree on Former (I mean Formal LOL).

Most here can agree that the P3 trial was flawed, the only logical explanation for the IPD/PSM package is that NWBO is attempting to

Frank Temp ICAV Frank S&...

Chesapeake Energy

FTSE RAFI All World 3000...

Investec Bnk 23

China Railway Signal and... (PK)

Restaurant Brands

Hikma Pharmaceuticals (PK)

Afl 3.80% 20apr52 Afl 3....

Aalo Atomics Share Cls L...

UBS Factor MSCI USA Qual...

BNP Paribas Issuance

FTSEurofirst 300 Retail

Delayed Upgrade Clock

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約

ADVFN

すでにアカウントをお持ちですか？サインイン

アカウントをお持ちでないですか？登録

登録することで、ADVFN の利用規約を読み、理解し、同意したこと、および私が個人投資家であることを確認します。